COMPARATIVE ANALYSIS OF MORTALITY FROM TUBERCULOSIS AMONG COUNTRIES OF FORMER SOVIET UNION

Mortality from tuberculosis has decreased from 11.89 deaths per 100,000 population in 1990 to 4.18 deaths per 100,000 population in Kazakhstan in 2019. Thus, the deviation was (-)35.5%. If Kazakhstan showed the above result over the 29-year period, then how are things with other republics that were part of the Soviet Union and how have the countries' economies changed? Aim - determination of the difference in 15 republics using the mortality rate from tuberculosis per 100,000 population. The study included the following countries: Ukraine, Georgia, Kazakhstan, Kyrgyzstan, Uzbekistan, Russia, Estonia, Lithuania, Latvia, Turkmenistan, Tajikistan, Belarus, Moldova, Azerbaijan, Armenia. The analysis was carried out using the Global burden of diseases database. A relatively high reduction in TB mortality was found in Kazakhstan (-3.61%). In second place is Estonia (-3.25%), in third place is Azerbaijan (-2.39%), in fourth place is Latvia (-2.16%), and the top five is closed by Georgia (-1.98%). Despite the high level of GDP, countries such as Russia (6th place in the world ranking of GDP per capita) and Ukraine (42nd place in the world ranking of GDP per capita) are not in the leading positions in reducing the burden of TB. For example, Russia is in 10th place (-0.81%) in terms of the percentage reduction in mortality from TB, and Ukraine is in last place. According to the Global Burden of Disease, Ukraine has seen an increase in TB mortality (+1.62%). The leader among the former Soviet countries in terms of spending on the healthcare system is Armenia (12.24%). In general, current public spending on health care per capita is 11.6 times lower than in OECD (Organization for Economic Cooperation and Development) member countries: in 2020 in Kazakhstan this indicator was 341.5 USD, in the OECD - on average 3 959 USD. According to WHO recommendations for sustainable development, financing of the health care system should be up to 5% of GDP, while the share of private spending should not exceed 20% of current health care spending. As the experience of developed countries shows, the level of life expectancy directly depends on the financing of the healthcare system.

The impact of the COVID-19 pandemic on tuberculosis case reporting in Kazakhstan

Background

The COVID-19 pandemic had a significant impact on economic development, lifestyles and health systems in all countries. Due to the lack of medical interventions, many countries adopted restrictive measures to slow the spread of the virus and reduce the burden on the healthcare system. Quarantine measures have had an impact on the transmission of SARS-CoV-2. However, the unintended consequences of such drastic measures were inevitable. In developing countries, there have been adverse effects of disruptions in health services, including the provision of timely medical services in detecting cases of tuberculosis in the population. The aim of this study was to study the influence of COVID-19 pandemic on the tuberculosis incidence in the Republic of Kazakhstan.

Methods

We analyzed national data on the reported tuberculosis cases and screening results of tuberculosis in Kazakhstan for 2019-2020. The primary data were collected from regular reporting of cases through surveillance.

Results

The number of registered patients identified during screening activities in 2020 were 2,854 cases compared to 4,288 cases in 2019 before COVID-19 era. The proportion of cases with antibiotic-resistant (poly, multi, super) forms of tuberculosis increased up to 6.7% in 2020 in comparison with 2019.

Conclusions

There is a need to conduct an analysis of the reasons for the increase in cases of multidrug-resistant and extensively drug-resistant tuberculosis. The working process should be adapted to epidemics and emergencies to ensure the availability of medical services, as well as to improve the system of preventive examinations and screening for the early detection of TB cases.

The abstract was submitted under the ‘CATINCA - Capacities and infrastructures for health policy development’ project which is coordinated/led by Robert Koch Institute and supported by the WHO Regional Office for Europe.

Key messages